미림진, "WARS1 타깃 자가면역질환 치료제 개발…내년 하반기 비임상 진입" / MirimGENE "Development of WARS1-targeted autoimmune disease therapy, launch of pre-clinical trials in the second half of next year."
POSTED ON August 17, 2023
CEO
Mirim Jin conducted an interview with HitNews
on the topic of “MirimGENE's core
pipeline status and future blueprint."
"We will leap forward as a biotech that leads the development of innovative new drugs (first-in-class) that can save the lives of autoimmune disease patients around the world. Currently, the manufacturing process (CMC) stage of the lead pipeline (new drug candidate) has been completed. “We plan to enter non-clinical trials in the second half of next year.” [ from article ]
Source : http://www.hitnews.co.kr/news/articleView.html?idxno=47468